Anticoagulant therapy
Warfarin, direct oral anticoagulants (DOACs), low-molecular-weight heparins, reversal agents, bridging decisions, and bleeding risk assessment — a clinical reference for prescribers and pharmacists.
Anticoagulant drug classes
| Class | Drug(s) | Target | Monitoring | Key notes |
|---|---|---|---|---|
| Vitamin K antagonist | Warfarin ↗ | Factors II, VII, IX, X (vitamin K-dependent) | INR 2–3 (most); 2.5–3.5 (mechanical valve) | Multiple DDIs; narrow TI; NTI drug |
| Direct thrombin inhibitor | Dabigatran ↗ | Factor IIa (thrombin) | None routine; aPTT qualitative | Renal: avoid CrCl <30; P-gp interactions |
| Direct factor Xa inhibitors | Apixaban ↗ | Factor Xa | None routine; anti-Xa if needed | Dose-reduce criteria (2.5 mg BD rule) |
| Rivaroxaban ↗ | Factor Xa | None routine | With food (↑F); avoid CrCl <15 | |
| Edoxaban ↗ | Factor Xa | None routine | Reduce to 30 mg if CrCl 15–50 | |
| Unfractionated heparin | UFH (IV) | Factors IIa, Xa (via AT-III) | aPTT or anti-Xa (IV infusion) | Reversible with protamine; HIT risk |
| LMWH | Enoxaparin, dalteparin | Factor Xa > IIa (via AT-III) | Anti-Xa trough (renal impairment, obesity) | Partial protamine reversal; renally cleared |
Warfarin INR management
Warfarin's anticoagulant effect is monitored by the International Normalised Ratio (INR). Target ranges depend on indication:
- AF, DVT/PE, bioprosthetic valve: INR 2.0–3.0
- Mechanical mitral valve: INR 2.5–3.5
- Mechanical aortic valve (bileaflet, low risk): INR 2.0–3.0
- Antiphospholipid syndrome (high risk): INR 2.5–3.5
Warfarin is metabolised primarily by CYP2C9 (S-warfarin, the more potent enantiomer) and CYP3A4 (R-warfarin). VKORC1 polymorphisms affect sensitivity to warfarin's effect. Together, CYP2C9 and VKORC1 genotypes explain ~40% of inter-individual dose variability. The WarfarinDosing.org calculator ↗ incorporates pharmacogenomics for initial dose estimation.
Key drug interactions increase INR risk: amiodarone (CYP2C9/3A4 inhibition), fluconazole, metronidazole, trimethoprim-sulfamethoxazole, and NSAIDs (↑bleeding risk without INR change). Enzyme inducers (rifampicin, carbamazepine, St John's wort) reduce warfarin effect. Dietary vitamin K (leafy greens) decreases INR — consistency of intake matters more than avoidance.
DOAC clinical considerations
DOACs offer predictable PK with fixed dosing and no routine coagulation monitoring. However, several clinical considerations apply:
Adherence is critical
DOACs have shorter half-lives than warfarin (dabigatran t½ ~12–17 h; apixaban ~12 h; rivaroxaban ~5–9 h; edoxaban ~10–14 h). Missing doses produces rapid loss of anticoagulant effect — unlike warfarin where the effect persists for days. Twice-daily dosing (apixaban, dabigatran) may improve adherence vs once-daily for some patients but requires consistent timing.
Drug interactions
All DOACs are P-glycoprotein (P-gp) substrates — strong P-gp inhibitors (ketoconazole, dronedarone) increase DOAC exposure. Dabigatran and rivaroxaban are also CYP3A4 substrates. Strong inducers (rifampicin, carbamazepine) substantially reduce exposure — avoid co-administration. See FDA DDI table ↗.
Measuring DOAC levels
When quantitative DOAC level measurement is needed (overdose, urgent surgery, renal failure, extreme body weight), anti-Xa assays calibrated to apixaban or rivaroxaban are used; dilute thrombin time (dTT) or ecarin clotting time (ECT) are used for dabigatran. Standard PT/aPTT are not reliable for DOAC quantification.
Not interchangeable
DOACs are not pharmacologically interchangeable — mechanism, dosing frequency, renal elimination, reversal agents, and DDI profiles differ substantially. Switching between DOACs or between DOACs and warfarin requires structured transition protocols to avoid over- or under-anticoagulation. ACCP antithrombotic guidelines ↗ provide transition protocols.
Reversal agents
| Anticoagulant | Reversal agent | Mechanism | Onset | Notes |
|---|---|---|---|---|
| Warfarin | Vitamin K (phytomenadione) | Replenishes vitamin K-dependent clotting factor synthesis | 6–24 h (oral); 1–2 h (IV) | Add 4F-PCC or FFP for life-threatening bleeding |
| Warfarin (urgent) | 4F-PCC (Kcentra) ↗ | Directly replaces factors II, VII, IX, X | Minutes | Preferred over FFP (lower volume, faster); thrombosis risk |
| Dabigatran | Idarucizumab (Praxbind) ↗ | Humanised antibody fragment binds dabigatran with 350× higher affinity than thrombin | Minutes | 5 g IV; complete reversal in >98% in RE-VERSE AD trial |
| Apixaban / Rivaroxaban / Edoxaban | Andexanet alfa (Andexxa) ↗ | Recombinant modified factor Xa decoy — sequesters Xa inhibitors | Minutes | High-/low-dose regimens; thrombosis risk; ANNEXA-4 trial data |
| All Xa inhibitors (off-label) | 4F-PCC | Overwhelms Xa inhibitor effect by providing excess clotting factors | Minutes | Non-specific; used when andexanet unavailable |
| UFH | Protamine sulfate | Ionic binding neutralises heparin | Minutes | 1 mg per 100 units UFH; max 50 mg per dose |
Antidotes for heparin, enoxaparin (Lovenox), and warfarin
Understanding anticoagulant reversal agents — commonly searched as "antidotes" — is critical for managing life-threatening bleeding.
Lovenox (enoxaparin) antidote: The antidote for Lovenox (enoxaparin) is protamine sulfate ↗. Protamine is a positively charged protein that binds to the negatively charged heparin/LMWH molecule via ionic interaction, neutralising its anticoagulant effect. For enoxaparin, protamine provides only partial reversal (~60–80% of anti-Xa activity) because protamine fully neutralises the anti-IIa (thrombin) component but only partially reverses the anti-Xa component. Dosing: 1 mg protamine per 1 mg enoxaparin given in the preceding 8 hours (maximum 50 mg per dose). If enoxaparin was given >8 hours ago, 0.5 mg protamine per 1 mg enoxaparin. For unfractionated heparin (UFH), protamine provides complete reversal at 1 mg per 100 units of UFH.
Warfarin antidote: The antidote for warfarin depends on urgency. For non-urgent reversal (INR elevated but no active bleeding), oral vitamin K (phytonadione) ↗ 1–2.5 mg is used — INR normalises in 24–48 hours. For urgent/life-threatening bleeding, IV vitamin K 10 mg is combined with four-factor prothrombin complex concentrate (4F-PCC, Kcentra) ↗, which directly replaces vitamin K-dependent clotting factors (II, VII, IX, X) and normalises INR within minutes. 4F-PCC is preferred over fresh frozen plasma (FFP) due to smaller volume, faster onset, and lower risk of transfusion reactions. See the NCBI warfarin reversal review ↗ for evidence-based protocols.